secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0001724521-25-000114
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Biosciences reports Q3 2025 net loss $135M; casdatifan shows 12.2 mo mPFS in late-line kidney cancer
--------------------------------------------------------------------------------

- Net loss of $135M for Q3 2025 vs $92M in Q3 2024; revenue $26M vs $48M.
- Casdatifan pooled analysis (n=121) showed 12.2 months median PFS and 35% ORR at 100mg dose in late-line ccRCC.
- Taiho exercised option for casdatifan in Japan/Asia for option payment, milestones, and royalties.
- Cash and equivalents $841M; funded through PEAK-1 Phase 3 readout.
- Domvanalimab + zimberelimab + chemo showed 26.7 months median OS in EDGE-Gastric study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452125000114/0001724521-25-000114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452125000114/rcus-20251028.htm
  HTML page:      https://secwatch.observer/filing/0001724521-25-000114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer